Contact Us | 1.617.500.7867 Overview Leadership Careers Benefits Contact Us Rare Disease Day EU Payment Disclosures 2015 EU Payment Disclosures 2014 EU Payment Disclosures 2013 EU Payment Disclosures What is HoFH? Development Programs JUXTAPID® MYALEPT® Contact Global Medical Information Overview Clinical Trials Physician Resources Global Medical Information Press Releases Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. 6.15.16- Aegerion Pharmaceuticals and QLT Inc. Agree to Strategic Merger 5.12.16- Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle with DOJ and SEC Related to Ongoing Investigation 2.29.16 - Aegerion Pharmaceuticals Observes Rare Disease Day 1.7.16 - Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer 11.20.15 - JUXTAPID™ (lomitapide) Capsules Available on the Régie de l'Assurance Maladie du Québec (RAMQ) for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) 11.10.15 - Aegerion Pharmaceuticals Announces Results from First Year of LOWER Study at AHA Scientific Sessions 2015 all news | subscribe to feed Symbol: AEGR Last Price: 2.970 Change: 0 Volume: 0 Quote Date: 9/30/2016 4:00:00 PM This page is intended exclusively for U.S. audiences. © 2012 Aegerion Pharmaceuticals, Inc. All rights reserved. AEGR/Global/167 07-14 Terms of Use | Contact Us | Site Map